Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53 -Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Asmita MishraRoni TamariAmy E DeZernMichael T ByrneMahasweta GooptuYi-Bin ChenH Joachim DeegDavid A SallmanPhillip GallacherAnders WennborgDenice K HickmanEyal C AttarHugo F FernandezPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
AML and MDS, post-HCT maintenance therapy with eprenetapopt combined with azacitidine was well tolerated. RFS and OS outcomes were encouraging in this high-risk population.